Lead Product(s): HFB30132A
Therapeutic Area: Infections and Infectious Diseases Product Name: HFB30132A
Highest Development Status: Phase I Product Type: Large molecule
Partner/Sponsor/Collaborator: HiFiBiO Therapeutics
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Partnership November 23, 2020
The partnership aims to advance HFB30132A, a SARS-CoV-2 neutralizing antibody for the treatment of COVID-19, through clinical development and commercial sale in Russia, pending approval from the Ministry of Health of the Russian Federation.